Angiogenesis patch trial moves forward:
This article was originally published in Clinica
Advanced Tissue Sciences has begun a pivotal preclinical trial of its tissue-engineered epicardial patch for stimulating new blood vessel growth and improving the function of damaged heart tissue. The trial will assess the safety of the patch, called Anginera, in large animals. A previous study in mice has shown that the patch can improve overall function in damaged heart tissue without adversely effecting normal heart tissue function. Studies in large animals are required by the US FDA before starting human trials, noted the La Jolla, California firm. An efficacy trial in large animals is to begin this summer.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.